Clinical Trials Directory

Trials / Completed

CompletedNCT00212862

Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia

Dosing and Outcomes Study of Erythropoietic Stimulating Therapies

Status
Completed
Phase
Study type
Observational
Enrollment
2,130 (actual)
Sponsor
Ortho Biotech Products, L.P. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to describe patient characteristics, treatment patterns, and clinical outcomes in adult patients with cancer who are receiving erythropoiesis-stimulating therapy (EST).

Detailed description

The Dosing and Outcomes Study of Erythropoietic Stimulating Therapies (DOSE) is a prospective, observational multicenter registry of approximately 1200 adult cancer patients receiving treatment with EST; eg, epoetin alfa or darbepoetin alfa. The planned duration of the DOSE Registry is three years. Based on initial results, the registry sponsor may elect to extend the duration of the registry.This study does not specify treatment protocols, require any particular assignment of patients to treatment protocols, or in any other way require participating physicians to alter their practice patterns. Participating physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on baseline patient characteristics, treatment patterns, and clinical outcomes. Baseline determinations will include patient demographics, tumor and treatment type, hematologic parameters, and patient reported outcomes. Data will be collected over the 16-week study period with regard to EST treatment, hematologic outcomes and patient reported outcomes.

Conditions

Interventions

TypeNameDescription
OTHERPatients with chemotherapy induced anemiaPhysicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.

Timeline

Start date
2003-12-01
Primary completion
2009-07-01
Completion
2009-07-01
First posted
2005-09-21
Last updated
2014-06-30

Source: ClinicalTrials.gov record NCT00212862. Inclusion in this directory is not an endorsement.